Table 3.
Colorectal cancer member characteristics by stage, diagnosed 2016–2020 (N = 2,407)
| Stage | I | II | III | IV |
|---|---|---|---|---|
| n (%)a, b | 269 (11.2%) | 581 (24.1%) | 914 (38.0%) | 643 (26.7%) |
| Age, mean (SD), yearsb | 63.2 (12.5) | 62.2 (13.8) | 61.0 (13.0) | 58.8 (13.2) |
| Female Gender, n (%)b | 132 (49.1%) | 267 (46.0%) | 434 (47.5%) | 298 (46.4%) |
| Insurance Type, n (%)a, b | ||||
| Commercial | 126 (46.8%) | 269 (46.3%) | 456 (49.9%) | 342 (53.2%) |
| Medicaid | 7 (2.6%) | 32 (5.5%) | 53 (5.8%) | 44 (6.8%) |
| Medicare Advantage | 120 (44.6%) | 255 (43.9%) | 335 (36.7%) | 201 (31.3%) |
| Multiplec | 0 (0.0%) | 1 (0.17%) | 0 (0.0%) | 0 (0.0%) |
| Unknown | 16 (6.0%) | 24 (4.1%) | 70 (7.7%) | 56 (8.7%) |
| Geographic Region, n (%)a, b | ||||
| Midwest | 115 (42.8%) | 244 (42.0%) | 379 (41.5%) | 269 (41.8%) |
| Northeast | 83 (30.9%) | 187 (32.2%) | 313 (34.3%) | 167 (26.0%) |
| South | 42 (15.6%) | 84 (14.5%) | 128 (14.0%) | 130 (20.2%) |
| West | 21 (7.8%) | 42 (7.2%) | 57 (6.2%) | 54 (8.4%) |
| Unknown | 8 (3.0%) | 24 (4.1%) | 37 (4.1%) | 23 (3.6%) |
| CCI, mean (SD)d | 1.3 (1.6) | 1.2 (1.7) | 1.2 (1.7) | 1.3 (1.6) |
| CCI, n (%)a, d | ||||
| 0 | 70 (41.9%) | 160 (47.9%) | 243 (49.0%) | 134 (37.1%) |
| 1 | 46 (27.5%) | 82 (24.6%) | 112 (22.6%) | 114 (31.6%) |
| 2 | 23 (13.8%) | 38 (11.4%) | 58 (11.7%) | 53 (14.7%) |
| ≥ 3 | 28 (16.8%) | 54 (16.2%) | 83 (16.7%) | 60 (16.6%) |
Charlson Comorbidity Index; SD Standard deviation
a Percentages may not total to 100% due to rounding
b Demographics were calculated at the time of cancer diagnosis
c Individuals had insurance eligibility from multiple types during this period
d CCI was calculated among subjects with 6 months of continuous insurance eligibility prior to their cancer diagnosis